2014
DOI: 10.1101/gr.165126.113
|View full text |Cite
|
Sign up to set email alerts
|

RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas

Abstract: Studies of gene rearrangements and the consequent oncogenic fusion proteins have laid the foundation for targeted cancer therapy. To identify oncogenic fusions associated with glioma progression, we catalogued fusion transcripts by RNA-seq of 272 gliomas. Fusion transcripts were more frequently found in high-grade gliomas, in the classical subtype of gliomas, and in gliomas treated with radiation/temozolomide. Sixty-seven in-frame fusion transcripts were identified, including three recurrent fusion transcripts… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

12
326
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 344 publications
(350 citation statements)
references
References 46 publications
12
326
1
Order By: Relevance
“…Although MET exon 14 splicing variants have not been identified to date in glioblastoma (GBM), alterations in the MET gene (such as amplifications and gene fusions), resulting in the constitutive activation of the Met receptor, have been reported (64,65). Moreover, a novel intragenic variant of Met-deleted receptor was found overexpressed in the 6% of high-grade gliomas.…”
Section: Brain and Nervous System Cancermentioning
confidence: 99%
“…Although MET exon 14 splicing variants have not been identified to date in glioblastoma (GBM), alterations in the MET gene (such as amplifications and gene fusions), resulting in the constitutive activation of the Met receptor, have been reported (64,65). Moreover, a novel intragenic variant of Met-deleted receptor was found overexpressed in the 6% of high-grade gliomas.…”
Section: Brain and Nervous System Cancermentioning
confidence: 99%
“…As a consequence of such treatment-driven and molecular type-dependent evolution, recGBs may considerably deviate in their molecular landscapes from precursor tumors. In agreement with this hypothesis, comparative profiling has revealed considerable differences between ndGBs and recGBs in mutational spectrum, frequency of genomic rearrangemens and gene expression patterns [29,30]. Notably, a considerable number of fusion transcripts identified in recGBs involve genes that have not previously been associated with gliomas suggesting that therapeutically actionable lesions in recGBs may differ from those identified in ndGBs.…”
Section: Glioblastoma: General Factsmentioning
confidence: 49%
“…The second training data contains 96 RNA-seq samples from seven studies, including pilocytic astrocytoma (n=7) [21], thyroid cancer (n=5) [22], glioblastoma (n=47) [23], lung adenocarcinoma (n=28) [24], ependymoma (n=7) [25], lung cancer liver metastasis (n=1) [26], and biphenotypic sinonasal sarcoma (n=1) [27]. Those samples, including 126 experimentally verified fusion genes, were used to optimize the score weights.…”
Section: Training Datamentioning
confidence: 99%